Proposed Information Collection Activity; State Plan Child Support Collection and Establishment of Paternity Title IV-D of the Social Security Act, 2931-2932 [2023-00764]
Download as PDF
<![CDATA[
2931
Federal Register / Vol. 88, No. 11 / Wednesday, January 18, 2023 / Notices
Dated: January 12, 2023.
William N. Parham, III,
Director, Paperwork Reduction Staff, Office
of Strategic Operations and Regulatory
Affairs.
[FR Doc. 2023–00879 Filed 1–17–23; 8:45 am]
BILLING CODE 4120–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Medicare & Medicaid
Services
[CMS–9896–N2]
Virtual Meeting of the Ground
Ambulance and Patient Billing
Advisory Committee; Cancellation
Centers for Medicare &
Medicaid Services (CMS), Health and
Human Services (HHS).
ACTION: Notice.
AGENCY:
The Centers for Medicare &
Medicaid Services is cancelling the
virtual public meeting of the Ground
Ambulance and Patient Billing, which
was scheduled for January 17 and 18,
2023.
FOR FURTHER INFORMATION CONTACT:
Shaheen Halim, CMS, by phone (410)
786–0641 or via email at
gapbadvisorycommittee@cms.hhs.gov.
Press inquiries may be submitted by
phone (202) 690–6145 or via email at
press@cms.hhs.gov.
SUPPLEMENTARY INFORMATION: This
notice announces the cancellation of the
January 17 and 18, 2023 virtual public
meeting of the Ground Ambulance and
Patient Billing (GAPB) that was
announced in the December 16, 2022
Federal Register (87 FR 77122 through
77123). The January 17 and 18, 2023
public meeting would have been the
initial plenary meeting of the GAPB
Advisory Committee. CMS will publish
a notice in the Federal Register
announcing the future, rescheduled
dates on which the initial meeting of the
GAPB Advisory Committee will take
place no less than 15 calendar days
SUMMARY:
before the meeting date. The meeting
will be open to the public in accordance
with the Federal Advisory Committee
Act.
The GAPB Advisory Committee will
make recommendations with respect to
disclosure of charges and fees for
ground ambulance services and
insurance coverage, consumer
protection and enforcement authorities
of the Departments of Labor, Health and
Human Services, and the Treasury (the
Departments) and relevant States, and
the prevention of balance billing to
consumers. The recommendations shall
address options, best practices, and
identified standards to prevent
instances of balance billing; steps that
can be taken by State legislatures, State
insurance regulators, State attorneys
general, and other State officials as
appropriate, consistent with current
legal authorities regarding consumer
protection; and legislative options for
Congress to prevent balance billing.
The Administrator of CMS, Chiquita
Brooks-LaSure, having reviewed and
approved this document, authorizes
Lynette Wilson, who is the Federal
Register Liaison, to electronically sign
this document for purposes of
publication in the Federal Register.
Dated: January 12, 2023.
Lynette Wilson,
Federal Register Liaison, Centers for Medicare
& Medicaid Services.
[FR Doc. 2023–00903 Filed 1–13–23; 4:15 pm]
BILLING CODE 4120–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Administration for Children and
Families
Proposed Information Collection
Activity; State Plan Child Support
Collection and Establishment of
Paternity Title IV–D of the Social
Security Act
Children and Families, U.S. Department
of Health and Human Services.
ACTION:
Request for public comments.
The Office of Child Support
Enforcement (OCSE), Administration for
Children and Families (ACF), U.S.
Department of Health and Human
Services (HHS), is requesting a 3-year
extension of the forms OCSE–21–U4:
Transmittal and Notice of Approval of
State Plan Material for: Title IV–D of the
Social Security Act, and OCSE–100:
State Plan (Office of Management and
Budget (OMB) # 0970–0017, expiration
July 31, 2023). No changes are proposed.
SUMMARY:
Comments due within 60 days of
publication. In compliance with the
requirements of the Paperwork
Reduction Act of 1995, ACF is soliciting
public comment on the specific aspects
of the information collection described
above.
DATES:
You can obtain copies of the
proposed collection of information and
submit comments by emailing
infocollection@acf.hhs.gov. Identify all
requests by the title of the information
collection.
ADDRESSES:
SUPPLEMENTARY INFORMATION:
Description: OCSE has approved an
IV–D state plan for each state. Federal
regulations require states to amend their
state plans only when necessary to
reflect new or revised federal statutes or
regulations or material change in any
state laws, regulations, policies, or IV–
D agency procedures. The requirement
for submission of a state plan and plan
amendments for the Child Support
Enforcement program is found in
sections 452, 454, and 466 of the Social
Security Act.
Respondents: State IV–D Agencies.
Office of Child Support
Enforcement, Administration for
AGENCY:
ANNUAL BURDEN ESTIMATES
Total
number of
respondents
lotter on DSK11XQN23PROD with NOTICES1
Instrument
State Plan (OCSE–100) ..................................................................................
State Plan Transmittal (OCSE–21–U4) ...........................................................
Estimated Total Annual Burden
Hours: 486.
VerDate Sep<11>2014
17:41 Jan 17, 2023
Jkt 259001
54
54
Comments: The Department
specifically requests comments on (a)
whether the proposed collection of
PO 00000
Frm 00055
Fmt 4703
Sfmt 4703
Annual
number of
responses per
respondent
12
12
Average
burden hours
per response
.5
.25
Annual
burden hours
324
162
information is necessary for the proper
performance of the functions of the
agency, including whether the
E:\FR\FM\18JAN1.SGM
18JAN1
2932
Federal Register / Vol. 88, No. 11 / Wednesday, January 18, 2023 / Notices
information shall have practical utility;
(b) the accuracy of the agency’s estimate
of the burden of the proposed collection
of information; (c) the quality, utility,
and clarity of the information to be
collected; and (d) ways to minimize the
burden of the collection of information
on respondents, including through the
use of automated collection techniques
or other forms of information
technology. Consideration will be given
to comments and suggestions submitted
within 60 days of this publication.
Authority: 42 U.S.C 652, 654, and 666.
John M. Sweet, Jr.,
ACF/OPRE Certifying Officer.
[FR Doc. 2023–00764 Filed 1–17–23; 8:45 am]
BILLING CODE 4184–41–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2022–D–2827]
Optimizing the Dosage of Human
Prescription Drugs and Biological
Products for the Treatment of
Oncologic Diseases; Draft Guidance
for Industry; Availability
AGENCY:
Food and Drug Administration,
Notice of availability.
The Food and Drug
Administration (FDA or Agency) is
announcing the availability of a draft
guidance for industry entitled
‘‘Optimizing the Dosage of Human
Prescription Drugs and Biological
Products for the Treatment of Oncologic
Diseases.’’ This guidance is intended to
assist sponsors in identifying the
optimal dosage(s) for human
prescription drugs or biological
products for the treatment of oncologic
diseases during clinical development
prior to submitting an application for
approval for a new indication and
usage. This guidance does not address
selection of the starting dosage for firstin-human trials nor does it address
dosage optimization for
radiopharmaceuticals, cellular and gene
therapy products, microbiota, or cancer
vaccines.
DATES: Submit either electronic or
written comments on the draft guidance
by March 20, 2023 to ensure that the
Agency considers your comment on this
draft guidance before it begins work on
the final version of the guidance.
ADDRESSES: You may submit comments
on any guidance at any time as follows:
lotter on DSK11XQN23PROD with NOTICES1
SUMMARY:
VerDate Sep<11>2014
17:41 Jan 17, 2023
Jkt 259001
Submit electronic comments in the
following way:
• Federal eRulemaking Portal:
https://www.regulations.gov. Follow the
instructions for submitting comments.
Comments submitted electronically,
including attachments, to https://
www.regulations.gov will be posted to
the docket unchanged. Because your
comment will be made public, you are
solely responsible for ensuring that your
comment does not include any
confidential information that you or a
third party may not wish to be posted,
such as medical information, your or
anyone else’s Social Security number, or
confidential business information, such
as a manufacturing process. Please note
that if you include your name, contact
information, or other information that
identifies you in the body of your
comments, that information will be
posted on https://www.regulations.gov.
• If you want to submit a comment
with confidential information that you
do not wish to be made available to the
public, submit the comment as a
written/paper submission and in the
manner detailed (see ‘‘Written/Paper
Submissions’’ and ‘‘Instructions’’).
Written/Paper Submissions
HHS.
ACTION:
Electronic Submissions
Submit written/paper submissions as
follows:
• Mail/Hand Delivery/Courier (for
written/paper submissions): Dockets
Management Staff (HFA–305), Food and
Drug Administration, 5630 Fishers
Lane, Rm. 1061, Rockville, MD 20852.
• For written/paper comments
submitted to the Dockets Management
Staff, FDA will post your comment, as
well as any attachments, except for
information submitted, marked and
identified, as confidential, if submitted
as detailed in ‘‘Instructions.’’
Instructions: All submissions received
must include the Docket No. FDA–
2022–D–2827 for ‘‘Optimizing the
Dosage of Human Prescription Drugs
and Biological Products for the
Treatment of Oncologic Diseases.’’
Received comments will be placed in
the docket and, except for those
submitted as ‘‘Confidential
Submissions,’’ publicly viewable at
https://www.regulations.gov or at the
Dockets Management Staff between 9
a.m. and 4 p.m., Monday through
Friday, 240–402–7500.
• Confidential Submissions—To
submit a comment with confidential
information that you do not wish to be
made publicly available, submit your
comments only as a written/paper
submission. You should submit two
copies total. One copy will include the
PO 00000
Frm 00056
Fmt 4703
Sfmt 4703
information you claim to be confidential
with a heading or cover note that states
‘‘THIS DOCUMENT CONTAINS
CONFIDENTIAL INFORMATION.’’ The
Agency will review this copy, including
the claimed confidential information, in
its consideration of comments. The
second copy, which will have the
claimed confidential information
redacted/blacked out, will be available
for public viewing and posted on
https://www.regulations.gov. Submit
both copies to the Dockets Management
Staff. If you do not wish your name and
contact information to be made publicly
available, you can provide this
information on the cover sheet and not
in the body of your comments and you
must identify this information as
‘‘confidential.’’ Any information marked
as ‘‘confidential’’ will not be disclosed
except in accordance with 21 CFR 10.20
and other applicable disclosure law. For
more information about FDA’s posting
of comments to public dockets, see 80
FR 56469, September 18, 2015, or access
the information at: https://
www.govinfo.gov/content/pkg/FR-201509-18/pdf/2015-23389.pdf.
Docket: For access to the docket to
read background documents or the
electronic and written/paper comments
received, go to https://
www.regulations.gov and insert the
docket number, found in brackets in the
heading of this document, into the
‘‘Search’’ box and follow the prompts
and/or go to the Dockets Management
Staff, 5630 Fishers Lane, Rm. 1061,
Rockville, MD 20852, 240–402–7500.
You may submit comments on any
guidance at any time (see 21 CFR
10.115(g)(5)).
Submit written requests for single
copies of the draft guidance to the
Division of Drug Information, Center for
Drug Evaluation and Research, Food
and Drug Administration, 10001 New
Hampshire Ave., Hillandale Building,
4th Floor, Silver Spring, MD 20993–
0002; or Office of Communication,
Outreach and Development, Center for
Biologics Evaluation and Research,
Food and Drug Administration, 10903
New Hampshire Ave., Bldg. 71, Rm.
3128, Silver Spring, MD 20993–0002.
Send one self-addressed adhesive label
to assist that office in processing your
requests. See the SUPPLEMENTARY
INFORMATION section for electronic
access to the draft guidance document.
FOR FURTHER INFORMATION CONTACT:
Mirat Shah, Center for Drug Evaluation
and Research (HFD–150), Food and
Drug Administration, 10903 New
Hampshire Ave., Silver Spring, MD
20993–0002, 301–796–8547; or Stephen
Ripley, Center of Biologics Evaluation
E:\FR\FM\18JAN1.SGM
18JAN1
]]>Agencies
[Federal Register Volume 88, Number 11 (Wednesday, January 18, 2023)]
[Notices]
[Pages 2931-2932]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-00764]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Administration for Children and Families
Proposed Information Collection Activity; State Plan Child
Support Collection and Establishment of Paternity Title IV-D of the
Social Security Act
AGENCY: Office of Child Support Enforcement, Administration for
Children and Families, U.S. Department of Health and Human Services.
ACTION: Request for public comments.
-----------------------------------------------------------------------
SUMMARY: The Office of Child Support Enforcement (OCSE), Administration
for Children and Families (ACF), U.S. Department of Health and Human
Services (HHS), is requesting a 3-year extension of the forms OCSE-21-
U4: Transmittal and Notice of Approval of State Plan Material for:
Title IV-D of the Social Security Act, and OCSE-100: State Plan (Office
of Management and Budget (OMB) # 0970-0017, expiration July 31, 2023).
No changes are proposed.
DATES: Comments due within 60 days of publication. In compliance with
the requirements of the Paperwork Reduction Act of 1995, ACF is
soliciting public comment on the specific aspects of the information
collection described above.
ADDRESSES: You can obtain copies of the proposed collection of
information and submit comments by emailing [email protected].
Identify all requests by the title of the information collection.
SUPPLEMENTARY INFORMATION:
Description: OCSE has approved an IV-D state plan for each state.
Federal regulations require states to amend their state plans only when
necessary to reflect new or revised federal statutes or regulations or
material change in any state laws, regulations, policies, or IV-D
agency procedures. The requirement for submission of a state plan and
plan amendments for the Child Support Enforcement program is found in
sections 452, 454, and 466 of the Social Security Act.
Respondents: State IV-D Agencies.
Annual Burden Estimates
----------------------------------------------------------------------------------------------------------------
Annual number Average burden
Instrument Total number of responses hours per Annual burden
of respondents per respondent response hours
----------------------------------------------------------------------------------------------------------------
State Plan (OCSE-100)........................... 54 12 .5 324
State Plan Transmittal (OCSE-21-U4)............. 54 12 .25 162
----------------------------------------------------------------------------------------------------------------
Estimated Total Annual Burden Hours: 486.
Comments: The Department specifically requests comments on (a)
whether the proposed collection of information is necessary for the
proper performance of the functions of the agency, including whether
the
[[Page 2932]]
information shall have practical utility; (b) the accuracy of the
agency's estimate of the burden of the proposed collection of
information; (c) the quality, utility, and clarity of the information
to be collected; and (d) ways to minimize the burden of the collection
of information on respondents, including through the use of automated
collection techniques or other forms of information technology.
Consideration will be given to comments and suggestions submitted
within 60 days of this publication.
Authority: 42 U.S.C 652, 654, and 666.
John M. Sweet, Jr.,
ACF/OPRE Certifying Officer.
[FR Doc. 2023-00764 Filed 1-17-23; 8:45 am]
BILLING CODE 4184-41-P
